JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT

约翰霍普金斯大学成人艾滋病临床试验中心

• 批准号: 6021497
• 负责人: JOHN G BARTLETT
• 金额: $ 130.45万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6021497
• 关键词: AIDS; AIDS /HIV neuropathy; AIDS related neoplasm /cancer; AIDS therapy; HIV infections; Histoplasma; Mycobacterium avium; Mycobacterium tuberculosis; Pneumocystis pneumonia; antiAIDS agent; antiviral antibody; body composition; cardiovascular disorder; cardiovascular disorder prevention; clinical research; clinical trial phase I; cooperative study; cytomegalovirus; drug adverse effect; drug interactions; experimental designs; gender difference; glucose metabolism; hepatitis B virus group; hepatitis C virus; human immunodeficiency virus 1; human subject; human therapy evaluation; hydroxyurea; immunoregulation; immunotherapy; latent virus infection; lipid metabolism; longitudinal human study; nucleoside analog; nucleotide analog; nutrition; opportunistic infections; outcomes research; pathologic process; pharmacokinetics; prodrugs; protease inhibitor; statistics /biometry; therapy compliance

DESCRIPTION (adapted from applicant's abstract): Johns Hopkins University has had an ACTU since its inception in 1986. The Unit is administratively within the Division of Infectious Diseases as a component of the Johns Hopkins HIV Care Program, but it is configured to make maximum use of relevant institutional resources with investigators from multiple departments and divisions including Pharmacology, Neurology, Ophthalmology, Gynecology, Pathology and Internal Medicine. The Hopkins ACTU has provided leadership to the ACTG scientific agenda and has provided HIV clinical trials to Baltimore, a city that ranks ninth among metropolitan areas in AIDS rates. The performance record for the last grant cycle shows average enrollment, data performance and a rank of No. 3 in scientific contributions. Assets of this ACTU include leadership and scientific expertise in virology (B. Jackson), immunology (H. Lederman, T. Quinn, R. Bollinger), quality of life assessment (A. Wu), neurology (J. McArthur), pharmacology (C. Flexner), CMV retinitis (D. Jabs), and mycobacteriology (R. Chaisson). This unit has a subunit in the prison system, has developed an ACTG study of tuberculosis in Haiti and has high enrollment of injection drug users and African-Americans. This application proposes to continue a scientific portfolio that has depth and diversity to support the ACTG scientific agenda and a clinical trials program that includes good data performance and the enrollment of high priority participants. All current investigators will continue in their present roles as will the three advanced technology laboratories. Three new investigators, Dr. R. Siliciano (latent reservoirs of HIV), Dr. Richard Moore (HIV outcomes, cost and cost effectiveness), and Dr. David Thomas (hepatitis C co-infection) will be added. Preference will be given to protocols that reflect emphasis areas of the Hopkins ACTU, especially pharmacology, neurology, immunology, mycobacteriology, hepatitis C, long-term outcomes (quality of life and cost analyses) and simplified ART regimens (to better serve the patients). There will be emphasis on enhanced enrollment with a new peer recruiter and a new subunit to increase the catchment area.

描述（改编自申请人的摘要）：约翰·霍普金斯大学 自 1986 年成立以来就有一个 ACTU。该单位在行政上属于 传染病科作为约翰·霍普金斯大学艾滋病毒的组成部分 护理计划，但它被配置为最大限度地利用相关 来自多个部门的研究人员的机构资源和 科室包括药理学、神经病学、眼科、妇科、 病理学和内科。 霍普金斯大学 ACTU 为 ACTG 科学议程提供了领导，并已 为巴尔的摩提供艾滋病毒临床试验，该城市在美国排名第九 大都市地区的艾滋病发病率。 上次资助的绩效记录 周期显示平均入学率、数据表现以及排名第 3 科学贡献。 该 ACTU 的资产包括领导力和 病毒学（B. Jackson）、免疫学（H. Lederman、T. Quinn，R. Bollinger），生活质量评估（A. Wu），神经病学（J. McArthur）、药理学（C. Flexner）、CMV 视网膜炎（D. Jabs）和 分枝杆菌学（R. Chaisson）。 该单位在监狱系统中有一个分单位， 在海地开展了一项针对结核病的 ACTG 研究，并且入学率很高 注射吸毒者和非裔美国人。 该应用程序建议继续具有深度的科学组合 和多样性以支持 ACTG 科学议程和临床试验 计划包括良好的数据性能和高入学率 优先参与者。 目前所有的调查人员都将继续他们的工作 三个先进技术实验室也将发挥作用。 三新 研究人员：R. Siliciano 博士（HIV 潜伏者）、Richard Moore 博士 （艾滋病毒结果、成本和成本效益）和 David Thomas 博士（丙型肝炎 合并感染）将被添加。 将优先考虑以下协议 反映霍普金斯 ACTU 的重点领域，特别是药理学， 神经学、免疫学、分枝杆菌学、丙型肝炎、长期结果 （生活质量和成本分析）和简化的 ART 治疗方案（以更好地 为患者服务）。 重点是通过新的招生计划提高入学率 同行招聘人员和一个新的子单位以扩大服务范围。